Intron A
information and resources from the National Cancer Institute
NCI Thesaurus | Intron A
(Other name for: interferon alfa)NCI Thesaurus | Intron A
(Other name for: interferon alfa)
Interferon alfa-2b Schering Corp Jun 21 2002
Interferon alfa-2b Schering Corp Jun 21 2002
Interferon alfa-2b
Interferon alfa-2b, recombinant for injection is indicated as adjuvant to surgical treatment in patients 18 years of age or older with malignant melanoma who are free of disease but at high risk for systemic recurrence within 56 days of surgery.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for intralesional treatment of selected patients 18 years of age or older with condylomata acuminata involving external surfaces of the genital and perianal areas.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for the initial treatment of clinically aggressive follicular Non-Hodgkin’s Lymphoma in conjunction with anthracycline-containing combination chemotherapy in patients 18 years of age or older.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of chronic hepatitis B in patients 18 years of age or older with compensated liver disease and HBV replication.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of chronic hepatitis C in patients 18 years of age or older with compensated liver disease who have a history of blood or blood-product exposure and/or are HCV antibody positive.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of patients 18 years of age or older with hairy cell leukemia.
Schering Corp Nov 06 1997
Interferon alfa-2b
Interferon alfa-2b, recombinant for Injection is indicated for the treatment of selected patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune system as indicated by total CD4 count.
Schering Corp Nov 06 1997
|
|
|
|
news articles
Schering-Plough's Oral HCV Protease Inhibitor Demonstrates Potent ... Nov 14, 2005
PR Newswire (press release), Psychiatric adverse events, which include insomnia, were common (57%) with PEG-INTRON, but similar to INTRON A (58%). Depression was most common at 29%. ...
PEG-INTRON(R) and REBETOL(R) Combination Therapy Demonstrates ... Nov 12, 2005
Yahoo! News (press release) There are no new adverse events specific to PEG-INTRON as compared to INTRON® A (interferon alfa-2b, recombinant) for Injection, however, the incidence of ...
Schering-Plough Reports 2005 Third Quarter Financial Results Oct 24, 2005
PR Newswire (press release), 175 (10) 507 530 (4) Temodar 152 121 25 428 309 38 Integrilin 86 94 (8) 244 245 0 Rebetol 82 52 58 237 239 (1) Claritin Rx * 76 67 13 287 240 19 Intron A 72 81 ...
Hepatitis Combination Therapy Okay for Children: Study Nov 15, 2005
Hepatitis Neighborhood, Fifty-six children were assigned at random in this initial phase to take interferon alfa-2b (Intron-A) along with ribavirin in varying doses for 48 weeks. ...
Biolex Therapeutics Successfully Completes Phase 1 Study for First ... Oct 26, 2005
Yahoo! News (press release) In the Phase 1 study BLX-883 was safely administered at a clinically relevant dose and demonstrated bioactivity consistent with Intron® A, a currently ...
Biolex Therapeutics Successfully Completes Phase 1 Study for First ... Oct 26, 2005
PR Newswire (press release), The 12 participants who received the clinically relevant dose of 3 million international units also received the same dose of Intron A to allow for a direct ...
OctoPlus Initiates Clinical Trials With Locteron(TM), a Controlled ... Nov 2, 2005
Yahoo! News (press release) ...of three different doses of Locteron will be compared to controls consisting of the delivery vehicle, a placebo, and PEG-Intron® (a currently marketed longer ...
|
|
